Leonteq Securities AG Sells 4,784 Shares of Gilead Sciences, Inc. $GILD

Leonteq Securities AG lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 11,318 shares of the biopharmaceutical company’s stock after selling 4,784 shares during the quarter. Leonteq Securities AG’s holdings in Gilead Sciences were worth $1,577,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in GILD. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC raised its stake in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares during the period. Quattro Advisors LLC bought a new position in Gilead Sciences in the fourth quarter worth approximately $26,000. Wealth Preservation Advisors LLC boosted its holdings in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $28,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the transaction, the chief executive officer directly owned 607,133 shares in the company, valued at $76,674,826.57. This represents a 2.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 83,000 shares of company stock valued at $10,824,500. 0.30% of the stock is owned by insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $131.27 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock has a 50 day moving average price of $129.44 and a two-hundred day moving average price of $134.53. The firm has a market capitalization of $162.98 billion, a P/E ratio of 17.88 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $107.75 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the prior year, the business posted $1.81 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were issued a dividend of $0.82 per share. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is 44.69%.

Analyst Ratings Changes

Several research firms have recently commented on GILD. Royal Bank Of Canada restated a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Leerink Partners reduced their price target on shares of Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Morgan Stanley lowered their price objective on shares of Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $158.41.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.